Evidence map›Paper›PMID 41064542›Full record

ArticleCase reports in gastroenterology

Successful Treatment of Refractory Immune-Mediated Colitis and Duodenitis with Tofacitinib.

Noboru Misawa, Takuma Higurashi, Kojiro Inoue, Hitomi Suzuki, Shigeki Tamura, Masato Yoneda, Chisa Hori, Shoji Yamanaka, Atsushi Nakajima

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Noboru MisawaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Takuma HigurashiDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Kojiro InoueDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Hitomi SuzukiDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Shigeki TamuraDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Masato YonedaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.
Chisa HoriDepartment of Pathology, Yokohama City University Hospital, Yokohama, Japan.
Shoji YamanakaDepartment of Pathology, Yokohama City University Hospital, Yokohama, Japan.
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University School of Medicine, Yokohama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Immune-mediated colitis (IMC) is a common and potentially severe immune-related adverse event of immune checkpoint inhibitors (ICIs). Although corticosteroids and biologics are standard treatments, some cases remain refractory. Tofacitinib, a Janus kinase inhibitor, has shown promise in refractory IMC; however, evidence regarding its treatment effects remains limited. Case Presentation: Here, we present a case of pembrolizumab-induced IMC and duodenitis refractory to corticosteroids, infliximab, and vedolizumab. The patient was successfully treated after receiving a 30-day course of tofacitinib, which resulted in rapid symptom resolution and mucosal healing. No recurrence of colitis was observed 3 months after treatment cessation. Conclusion: As ICIs are increasingly used, the incidence of refractory IMC and other immune-related toxicities is expected to rise. This case highlights the need for further studies to establish the optimal use of tofacitinib in refractory IMC and duodenitis.

Indexed as

DuodenitisImmune checkpoint inhibitorsImmune-mediated colitisTofacitinib

Identifiers

PMID41064542
PMCPMC12503550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.